VISCHER advises GlycoVaxyn, a leader in the development of innovative vaccines, entering into a collaboration with GlaxoSmithKline Biologicals (GSK) to develop new bacterial vaccines. GlycoVaxyn is developing a portfolio of novel bio-conjugate vaccines with its unique, proprie-tary in vivo glycosylation platform. GlycoVaxyn located in Schlieren near Zurich is funded by a top-tier group of private investors including Sofinnova Partners, Index Ventures and Edmond de Rothschild Investment Partners. The VISCHER team is led by Matthias Staehelin (Corporate) with Christian Wyss.